Changhua Wang

Changhua Wang

Auto-generated profile, based on publicly available information

Changhua Wang

Department of Cardiology

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2011 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
YCYundai Chen
Yundai Chen
CWChanghua Wang
Changhua Wang
XYXinchun Yang
Xinchun Yang
LWLefeng Wang
Lefeng Wang
ZSZhijun Sun
Zhijun Sun
LCLian Chen
Lian Chen

31 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
JWJinwen Wang
Jinwen Wang
CWChanghua Wang
Changhua Wang
ZZZhechun Zeng
Zhechun Zeng
HZHuijuan Zuo
Huijuan Zuo
Aim. Obesity paradox remains a point of debate in ST‐segment elevation myocardial infarction (STEMI) patients. The aim of this study was to examine the relationship between body mass index (BMI) and clinical outcomes in STEMI patients undergoing primary percutaneous coronary intervention (PPCI). Methods. Outcomes were assessed in 1429 STEMI patients undergoing PPCI between January 2009 and January 2010 in Beijing. Patients were classified into 6 groups according to age (the younger and elderly groups consisting of patients ≤65 and > 65 years old) and baseline BMI (normal weight, BMI < 24 kg/m2; overweight, 24 kg/m2 ≤BMI < 28 kg/m2; obese, BMI ≥ 28 kg/m2). The primary outcome was death, acute myocardial infarction (AMI), or revascularization. Results. On long‐term follow‐up (mean follow‐up of 59 months), 13.9% of patients experienced the adverse event. Multivariate logistic regression analyses showed that low BMI was a significant predictor of the primary outcome only in the younger group. The odds ratio for overweight in comparison with normal weight was 0.741 (95% CI: 0.413–0.979; p = 0.038), the odds radio for obesity in comparison with normal‐weight patients was 0.508 (95% CI: 0.344–0.750; p = 0.016) in the younger group. In the elderly group, diabetes, hypertension, triple disease, regular exercise, angiotensin‐converting enzyme inhibitor (ACEI) or angiotensin II receptor blockers (ARBs) use after discharge, and bleeding complication were associated with primary outcome. Conclusion. The obesity paradox was recognized only in the younger age group in STEMI patients undergoing PPCI.

17 February 2011 in Scandinavian Cardiovascular Journal
Verified
Journal Article
Closed access
PDF file
CWChang-Hua Wang
Chang-Hua Wang
YCYun-Dai Chen
Yun-Dai Chen
XYXin-Chun Yang
Xin-Chun Yang
LWLe-Feng Wang
Le-Feng Wang
HWHong-Shi Wang
Hong-Shi Wang
HLHong-Bin Liu
Hong-Bin Liu
Objectives. This study was undertaken to assess independent no-reflow predictors in patients with ST-elevation acute myocardial infarction (STEMI) and primary drug-eluting stenting in the current interventional strategies. Design. One thousand four hundred and thirteen patients with STEMI were successfully treated with primary drug-eluting stenting within 12 h after AMI. All clinical, angiographic and procedural data were collected. Univariate and multivariate logistic regression was used to identify independent no-reflow predictors. Results. The no-reflow was found in 297 (21%) of 1413 patients. Univariate and multivariate logistic regression identified that age (>65 years, OR 1.47, 95% CI 1.46–1.49; p = 0.007), long time-to-reperfusion (>6 h, OR 1.27, 95% CI 1.16–1.40; p = 0.001), admission plasma glucose (>13.0 mmol/L, OR 1.27, 95% CI 1.16–1.40; p = 0.027), collateral circulation (0–1, OR 1.69, 95% CI 1.25–2.29; p = 0.001), pre-PCI thrombus score (≥4, OR 1.36, 95% CI 1.16–1.79; p = 0.011), and IABP use before PCI (OR 2.89, 95% CI 1.65–5.05; p < 0.0001) were independent no-reflow predictors. The no-reflow rate significantly increased as the number of independent predictors increased (0%, 6%, 15%, 25%, 40%, 50% and 100% in patients with 0, 1, 2, 3, 4, 5, and 6 independent predictors, respectively; p < 0.0001). Conclusions. The prediction model consisted of six no-reflow predictors in patients with STEMI and primary drug-eluting stenting and should be confirmed in large-scale prospective studies.